Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA-SON is a short hairpin RNA (shRNA) vector designed to target and knockdown the expression of the SON DNA-binding protein. SON is a large protein involved in various cellular processes, including RNA splicing and cell cycle regulation. In the context of pancreatic cancer, SON has been identified as a novel therapeutic target. Knockdown of SON using shRNA-SON has been shown to induce G2/M cell cycle arrest and apoptosis in pancreatic cancer cells, while having minimal effect on normal pancreatic duct epithelial cells. Preclinical studies in xenograft models demonstrated that stable expression of shRNA-SON significantly retards tumor formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shRNA-SON.